Candesartan Cilexetil Tablets, 16 mg, a) 30 count (NDC 00781-5938-31) and b) 90 count (NDC 00781-...

FDA Drug Recall #D-0659-2016 — Class III — December 31, 2015

Recall Summary

Recall Number D-0659-2016
Classification Class III — Low risk
Date Initiated December 31, 2015
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Sandoz Inc
Location Princeton, NJ
Product Type Drugs
Quantity 277,267 bottles

Product Description

Candesartan Cilexetil Tablets, 16 mg, a) 30 count (NDC 00781-5938-31) and b) 90 count (NDC 00781-5938-92) bottles, Rx Only, Manufactured by Mylan Laboratories Limited Hyderabad 500 034, India for Sandoz Inc. Princeton, NJ 08540

Reason for Recall

Failed Impurities/Degradation Specifications; 9 month stability timepoint

Distribution Pattern

Nationwide

Lot / Code Information

a) 3022288 12/2015 3025988 03/2016 3025989 04/2016 3030459 08/2016 3030460 08/2016 3032087 10/2016 3032088 10/2016 3034506 12/2016 3035952 01/2017 3035953 01/2017 b) 3022287 12/2015 3025990 04/2016 3030458 08/2016 3032086 09/2016 3035954 01/2017

Other Recalls from Sandoz Inc

Recall # Classification Product Date
D-0651-2025 Class II Cyclophosphamide Injection 500 mg/5 mL (100 mg/... Sep 5, 2025
D-0626-2025 Class II Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic ... Aug 13, 2025
D-0569-2025 Class I Cefazolin for Injection, USP, 1 gram per vial, ... Jun 27, 2025
D-0570-2025 Class I Buffered Penicillin G Potassium for Injection, ... Jun 27, 2025
D-0286-2022 Class I Enoxaparin Sodium Injection, USP, 40 mg/0.4 mL,... Nov 17, 2021

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.